Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Madrigal Pharmaceuticals, Inc. - Common Stock
(NQ:
MDGL
)
553.42
+24.21 (+4.57%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Madrigal Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio?
↗
November 09, 2025
Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps.
Via
Benzinga
Madrigal Pharmaceuticals (NASDAQ:MDGL) Q3 2025 Earnings: Revenue Beat and EPS Miss Drive Pre-Market Surge
↗
November 04, 2025
Madrigal's Q3 2025 earnings show Rezdiffra sales of $287.3M, crushing estimates. With over 29,500 patients on therapy, the stock surged on strong commercial uptake.
Via
Chartmill
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
A Look Ahead: Madrigal Pharmaceuticals's Earnings Forecast
↗
November 03, 2025
Via
Benzinga
Beyond The Numbers: 10 Analysts Discuss Madrigal Pharmaceuticals Stock
↗
October 15, 2025
Via
Benzinga
Earnings Scheduled For August 5, 2025
↗
August 05, 2025
Via
Benzinga
Earnings Scheduled For May 1, 2025
↗
May 01, 2025
Via
Benzinga
6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner
↗
September 30, 2025
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.
Via
Benzinga
A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 7 Analysts
↗
September 29, 2025
In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), showcasing a mix of bullish and bearish perspectives.
Via
Benzinga
MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) Screens as High-Growth Momentum Stock Meeting Minervini Trend Template
↗
September 24, 2025
Madrigal Pharmaceuticals (MDGL) meets Mark Minervini's high-growth trend template, showing explosive revenue growth and a perfect 10/10 technical rating.
Via
Chartmill
MarketBeat Week in Review – 09/08 - 09/12
↗
September 13, 2025
Markets had another strong week as inflaton data set the stage for the Federal Reserve’s meeting next week; a rate cut is expected but may already be priced in
Via
MarketBeat
Topics
Economy
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday
↗
September 12, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 6 Analysts
↗
September 12, 2025
Via
Benzinga
CoreWeave and Madrigal's Insider Trades Flash Bullish Signals
↗
September 10, 2025
Insider trades at NVIDIA-backed CoreWeave and Madrigal Pharmaceuticals are bullish indicators, but for very different reasons.
Via
MarketBeat
Topics
Artificial Intelligence
Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure
↗
August 28, 2025
Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment.
Via
Investor's Business Daily
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker
↗
August 26, 2025
HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billion potential and strong fibrosis treatment pipeline.
Via
Benzinga
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
↗
August 26, 2025
Via
Benzinga
Corporate Wins: Intel, Palo Alto Networks, and Novo Nordisk Drive Market Optimism
August 20, 2025
In a week marked by a surge of positive corporate news, three industry giants—Intel, Palo Alto Networks, and Novo Nordisk—have delivered significant boosts to investor confidence, signaling robust...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma
↗
August 18, 2025
The FDA will allow patients with MASH to undergo Wegovy treatment, hampering the only other company with an approved MASH drug.
Via
Investor's Business Daily
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
↗
August 18, 2025
FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth.
Via
Benzinga
Billionaire Investor Buys Google And This Gold Miner Stock
↗
August 16, 2025
John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet.
Via
Benzinga
Madrigal (MDGL) Q2 Revenue Soars 1,313%
↗
August 05, 2025
Via
The Motley Fool
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Beats Q2 2025 Revenue Estimates and Narrows Losses on Strong Rezdiffra Sales
↗
August 05, 2025
Madrigal Pharmaceuticals (MDGL) beats Q2 2025 revenue estimates with $212.8M, driven by strong Rezdiffra sales, narrowing losses. Stock rises 12.8% pre-market.
Via
Chartmill
European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug
↗
June 20, 2025
Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August.
Via
Benzinga
5 Health Care Stocks With Whale Alerts In Today's Session
↗
June 20, 2025
Via
Benzinga
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
↗
May 13, 2025
Via
The Motley Fool
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock
↗
May 11, 2025
Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment,...
Via
Stocktwits
Topics
Death
Uncovering Potential: Madrigal Pharmaceuticals's Earnings Preview
↗
April 30, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
April 25, 2025
Via
Benzinga
Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday
↗
February 26, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.